<p>First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>-Reference-Cited by-同舟云学术

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Published:2020-07 Issue: Volume:Volume 12 Page:5479-5489
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Tomao Federica^ORCID,Boccia Serena Maria,Sassu Carolina Maria,Chirra Martina^ORCID,Palaia Innocenza^ORCID,Petrella Maria Cristina,Di Donato Violante,Colombo Nicoletta^ORCID,Benedetti Panici Pierluigi

Publisher

Informa UK Limited

Subject

Oncology

Reference84 articles.

1. Percent of cases & 5-year relative survival by stage at diagnosis: ovarian cancer. Available from: https://seer.cancer.gov/statfacts/html/ovary.html. Accessed January 30, 2020.

2. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Française d'Oncologie Gynécologique)

3. Special issues in fertility preservation for gynecologic malignancies

4. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP Inhibitor Rechallenge Could be an Effective Strategy in Platinum-Sensitive Ovarian Cancer: A Retrospective Study;J BIOL REG HOMEOS AG;2024

2. Hereditary Breast and Ovarian Cancer;Obstetrics and Gynecology Clinics of North America;2022-03

3. Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model;Acta Biomaterialia;2021-09

4. Ovarian Cancer: Biomarkers and Targeted Therapy;Biomedicines;2021-06-18